Skip to main content

Table 1 Characteristics of the study patients

From: Time-varying serum gradient of hepatitis B surface antigen predicts risk of relapses after off-NA therapy

Characteristics All patients (N = 140)
Male gender, n (%) 109 (77.9%)
EOT Age, years 49.1 (39.2, 57.5)
EOT anti-HBe-positive, n (%) 131 (93.6%)
EOT HBsAg, log IU/mL 2.79 (2.13, 3.12)
EOT ALT, U/L 22 (16.5, 34)
EOT AFP, ng/ml 2.7 (1.97, 3.41)
Pretreatment HBeAg-positive, n (%) 39 (27.9%)
Pretreatment anti-HBe-positive, n (%) 100 (71.4%)
Pretreatment viral DNA, log IU/ml 6.21 (4.53, 7.67)
Pretreatment ALT, U/L 154 (95, 451)
On-therapy duration, month 36.6 (36.4, 37.0)
Off-therapy follow-upa, month 19.9 (10.6, 25.3)
Patients received Entecavir 125 (89.3%)
Patients received Tenofovir, 9 (6.4%)
Patients received Lamivudine or Telbivudine 6 (4.2%)
  1. Notes. apatients were followed up until reuse of antiviral therapy; AFP alpha-fetoprotein, ALT Alanine transaminase, EOT end-of-therapy, HBeAg hepatitis B e antigen, HBsAg hepatitis B surface antigen